For advanced colorectal cancer, the combination of 5-FU, CPT- 11, and oxaliplatin (termed as FOLFOX or FOLFIRI therapy) with the additional use of bevacizumab, is recommended as a standard therapy. Generally, 5-FU monotherapy is recommended in the treatment of relatively slowly progressing advanced colorectal cancer, which is equivalent to group 3 of colorectal cancer according to the ESMO guidelines. However, the best proper use of this therapy remains to be identified. Here, we report a case of complete response after treatment with prolonged UFT/LV regimen for liver and lung metastases of rectal cancer.
Complete Response after Treatment with UFT/LV Regimen for Liver and Lung Metastases of Rectal Cancer: A Case Report
Last date updated on July, 2014